2024-09-24 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, consumables, software, and services for research, healthcare, and industrial markets.

**Performance Summary:**

* **Relative Performance:** Compared to the S&P 500 (VOO), TMO has significantly outperformed with a cumulative return of 249.89% versus 133.1%. This places TMO at the 53.87% percentile of its historical performance range, indicating strong performance relative to the benchmark. 
* **Recent Price Action:**
    * Closing Price: $610.35
    * 5-day Moving Average: $612.89
    * 20-day Moving Average: $612.97
    * 60-day Moving Average: $589.56
    *  The recent price action suggests a slight downtrend with the 5-day and 20-day moving averages slightly above the current price and the 60-day moving average indicating a stronger uptrend in the past 2 months.
* **Technical Indicators:**
    * **RSI (Relative Strength Index):** 52.93, indicating a neutral momentum.
    * **PPO (Percentage Price Oscillator):** -0.22, suggesting a slight bearish bias.
    * **Delta_Previous_Relative_Divergence:** -0.86, implying a recent short-term downward trend in relative performance.
    * **Expected Return:** 101.57%, representing a potential 5-year maximum expected return on investment.
* **Recent Earnings Performance:**
    *  TMO has consistently exceeded revenue expectations in recent quarters. The most recent earnings report (2024-08-02) showed EPS of $4.05 and revenue of $10.54 billion, beating analyst expectations. 

**Overall Analysis:**

Thermo Fisher Scientific continues to demonstrate strong performance, exceeding the S&P 500 benchmark by a considerable margin. The company's robust earnings performance, supported by sustained revenue growth, indicates healthy fundamentals. 

While recent technical indicators point towards a slight short-term bearish bias, the long-term outlook remains positive due to the company's dominance in its sector and the continued potential for growth in the scientific and healthcare markets. 

Investors considering TMO should monitor the company's earnings releases, track key technical indicators, and carefully assess their risk tolerance before making any investment decisions. The expected return of 101.57%  highlights the potential for significant long-term gains. 
